NEC led a Series B-2 round in BostonGene.

Synopsis

NEC, a publicly traded Japanese IT services and product company, led a Series B-2 round in BostonGene, a US biomedical software corporation. Financial terms were not disclosed.

Principals

target

BOSTONGENE

bidder

Nec Corporation

Show Details & Financials

Did you work on this deal?

Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.

Market Context

white & case

HQ - New York

legal advisors

bidder

2064

Deals

£ 1,704.91 B

Total Value